Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-26
2007-06-26
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S295000, C544S363000
Reexamination Certificate
active
11546693
ABSTRACT:
Provided are compounds of formula (I)which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of formula I are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory disease or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, e.g. angiopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contract dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.
REFERENCES:
patent: 6645970 (2003-11-01), Albert et al.
patent: 0 328 026 (1989-08-01), None
patent: 1 120 414 (2001-08-01), None
patent: 01/46178 (2001-06-01), None
patent: 02/10158 (2002-02-01), None
patent: 02/38561 (2002-05-01), None
Evenou Jean-Pierre
Von Matt Peter
Wagner Jürgen
Zenke Gerhard
Barker Michael
Novartis AG
Savitsky Thomas R.
LandOfFree
Indolylmaleimide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolylmaleimide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolylmaleimide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3884177